Literature DB >> 28768850

Five cases of malignant melanoma during fingolimod treatment in Dutch patients with MS.

Joep Killestein1, Cyra E Leurs2, Erwin L J Hoogervorst2, Jeroen van Eijk2, Jop P Mostert2, Alfons J M van den Eertwegh2, Bernard M J Uitdehaag2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28768850     DOI： 10.1212/WNL.0000000000004293

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  4 in total

1.  Detection of a new melanoma in a patient treated with fingolimod.

Authors:  Yves Michiels; Olivier Bugnon; Jean-François Michiels; Sophie Mazellier
Journal:  BMJ Case Rep       Date:  2019-04-29

Review 2.  Cancer Risk in Patients with Multiple Sclerosis: Potential Impact of Disease-Modifying Drugs.

Authors:  Christine Lebrun; Fanny Rocher
Journal:  CNS Drugs       Date:  2018-10       Impact factor: 5.749

3.  Multiple Sclerosis Treatment and Melanoma Development.

Authors:  Maria Luigia Carbone; Pedro Miguel Lacal; Serena Messinese; Laura De Giglio; Carlo Pozzilli; Severino Persechino; Cinzia Mazzanti; Cristina Maria Failla; Gianluca Pagnanelli
Journal:  Int J Mol Sci       Date:  2020-04-22       Impact factor: 5.923

4.  Exacerbation of Multiple Sclerosis by BRAF/MEK Treatment for Malignant Melanoma: The Central Vein Sign to Distinguish Demyelinating Lesions From Metastases.

Authors:  Christopher C Hemond; Rohit Bakshi; Shahamat Tauhid; Rosila Sarrosa; Madison Ryan; Vineetha Kamath; James Thomas; Keith R Edwards
Journal:  J Investig Med High Impact Case Rep       Date:  2021 Jan-Dec
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.